Evidence map›Paper›PMID 26193421›Full record

ArticleFEBS letters2015

The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells.

Melania E Mercado-Pimentel, Benjamin C Onyeagucha, Qing Li, Angel C Pimentel, Jana Jandova, Mark A Nelson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Oncology letters · 2018
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Melania E Mercado-PimentelDepartment of Pathology, University of Arizona, Tucson, AZ 85724, USA; University of Arizona Cancer Center, Tucson, AZ, USA.
Benjamin C OnyeaguchaDepartment of Pathology, University of Arizona, Tucson, AZ 85724, USA; Cancer Biology Graduate Program, University of Arizona, USA.
Qing LiDepartment of Pathology, University of Arizona, Tucson, AZ 85724, USA.
Angel C PimentelDepartment of Molecular and Cell Biology, University of Arizona, USA.
Jana JandovaDepartment of Pathology, University of Arizona, Tucson, AZ 85724, USA; University of Arizona Cancer Center, Tucson, AZ, USA.
Mark A NelsonDepartment of Pathology, University of Arizona, Tucson, AZ 85724, USA; Cancer Biology Graduate Program, University of Arizona, USA; University of Arizona Cancer Center, Tucson, AZ, USA. Electronic address: mnelson@pathology.arizona.edu.
University of Arizona · USUniversity of Arizona Cancer Center

Funding

SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
NCI NIH HHS CA 95060NCI NIH HHS P50 CA095060
6 · The paper itself

Abstract

S100P signaling through the receptor for advanced glycation end-products (RAGE) contributes to colon cancer invasion and metastasis, but the mechanistic features of this process are obscure. Here, we investigate whether activation of S100P/RAGE signaling regulates oncogenic microRNA-21 (miR-21). We show that exogenous S100P up-regulates miR-21 levels in human colon cancer cells, whereas knockdown of S100P results in a decrease of miR-21. Furthermore, blockage of RAGE with anti-RAGE antibody suppresses S100P induction of miR-21. In addition, we found that S100P induction of miR-21 expression involves ERK and is suppressed by the MEK inhibitor U0126. Also, S100P treatment stimulates the enrichment of c-Fos, and AP-1 family members, at the miR-21 gene promoter.

Indexed as

Gene Expression Regulation, NeoplasticSignal TransductionCalcium-Binding ProteinsCell Line, TumorColonic NeoplasmsDatabases, GeneticGPI-Linked ProteinsHumansMicroRNAsNeoplasm ProteinsPromoter Regions, GeneticReceptor for Advanced Glycation End ProductsReceptors, ImmunologicTranscription Factor AP-1Transcription, GeneticUp-RegulationCalcium-Binding ProteinsGPI-Linked ProteinsMicroRNAsMIRN21 microRNA, humanNeoplasm ProteinsReceptor for Advanced Glycation End ProductsReceptors, ImmunologicRECK protein, humanS100P protein, humanTranscription Factor AP-1AP-1Colon cancerInflammationMetastasismicroRNAsmiR-21RAGERECKTCGA

Identifiers

PMID26193421
PMCPMC4582666
OpenAlexW1616842217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.